K. Meetze

发表

Profound, durable and MGMT‐independent sensitivity of glioblastoma cells to cyclin‐dependent kinase inhibition

M. Weller, É. Le Rhun, E. Szabó, 2019, International journal of cancer.

Preclinical antitumor activity with MLN8054, a small molecule Aurora A kinase inhibitor

K. Connolly, O. Burenkova, M. Manfredi, 2006 .

Abstract 3674: Pentarins: Improved tumor targeting through nanoparticle encapsulation of miniaturized biologic drug conjugates

D. Rockwood, R. Wooster, S. Kadiyala, 2015 .

Anticorps anti-ron

S. Weiler, J. Gyuris, L. Lerner, 2011 .

Abstract C173: Anti‐tumor activity of SCH 900105 (AV299), an anti‐HGF antibody, in non‐small cell lung cancer models

J. Gyuris, K. Connolly, W. Rideout, 2009 .

Abstract C181: Preclinical efficacy and pharmacodynamics of SCH 900105 (AV‐299) an anti‐HGF antibody in an intracranial glioblastoma model

J. Gyuris, K. Connolly, S. Medicherla, 2009 .

Novel Targeting of Transcription and Metabolism in Glioblastoma

M. Gilbert, Wei Zhang, D. Maric, 2017, Clinical Cancer Research.

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

Wei Chen, Suresh K Balani, G. Weatherhead, 2007, Proceedings of the National Academy of Sciences.

Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models

Richard Nicoletti, S. Weiler, J. Gyuris, 2014, Clinical Cancer Research.

GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.

Nhi N. Y. Vo, L. Poling, S. Weiler, 2010, Cancer research.

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL

P. Baeuerle, H. Salih, J. Michaelson, 2022, Journal for ImmunoTherapy of Cancer.

2LB Anti-tumor activity of anti-RON antibodies and biomarker of response

S. Weiler, J. Gyuris, K. Whalen, 2010 .

302 Antitumor Activity of Ficlatuzumab in Combination with Cetuximab On Squamous Cell Carcinomas of the Head and Neck

J. Gyuris, K. Connolly, K. Clark, 2012 .

Abstract 2509: AV-203, a humanized ERBB3 inhibitory antibody inhibits ligand-dependent and ligand-independent ERBB3 signaling in vitro and in vivo

S. Weiler, J. Gyuris, S. Bottega, 2012 .

MLN8054, an orally active Aurora A kinase small molecule inhibitor in phase I clinical trials

C. Claiborne, Wei Chen, T. Vos, 2006 .

1395 CLN 619 a clinical stage MICA B specific IgG1 antibody which restores the MICA B-NKG2D axis requires Fc function for potent anti-tumor activity

J. Michaelson, M. Naveen, K. Whalen, 2022, Regular and Young Investigator Award Abstracts.

Cancer esearch apeutics , Targets , and Chemical Biology 69 , an FGFR 2-IIIb – Specific Antibody , Exhibits Potent itumor Activity against Human Cancers Driven R ctivated FGFR 2 Signaling

L. Poling, J. Gyuris, Nesreen S. Ismail, 2010 .

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression

P. Baeuerle, J. Michaelson, Bochong Li, 2023, Journal for ImmunoTherapy of Cancer.

Abstract 2078: CLN-049 is a bispecific T cell engaging IgG-like antibody targeting FLT3 on AML cells

P. Baeuerle, J. Michaelson, Bochong Li, 2022, Cancer Research.

Abstract 4532: Preclinical evaluation of JTX-1811, an anti-CCR8 antibody with enhanced ADCC activity, for preferential depletion of tumor-infiltrating regulatory T cells

Changyun Hu, M. Gostissa, E. Stack, 2020, Immunology.

Preclinical pharmacodynamic studies of Aurora A inhibition by MLN8054.

K. Burke, O. Burenkova, K. Galvin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Profound, durable and MGMT‐independent sensitivity of glioblastoma cells to cyclin‐dependent kinase inhibition

M. Weller, É. Le Rhun, E. Szabó, 2019, International journal of cancer.